Capping Bioprosthetic Tissue to Reduce Calcification
First Claim
1. A method of mitigating calcification in bioprosthetic implant tissue, comprising:
- a) treating bioprosthetic implant tissue with a capping agent that reacts with functional groups on said tissue, andb) dehydrating the tissue with a non-aqueous solution.
1 Assignment
0 Petitions
Accused Products
Abstract
A treatment for bioprosthetic tissue used in implants or for assembled bioprosthetic heart valves to reduce in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.
308 Citations
26 Claims
-
1. A method of mitigating calcification in bioprosthetic implant tissue, comprising:
-
a) treating bioprosthetic implant tissue with a capping agent that reacts with functional groups on said tissue, and b) dehydrating the tissue with a non-aqueous solution. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
-
-
13. A bioprosthetic implant tissue, comprising:
-
a) bioprosthetic implant tissue that has been treated with a capping agent which reacts with functional groups on said tissue, and b) dehydrated with a non-aqueous solution. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
-
25. A bioprosthetic heart valve, comprising:
-
bioprosthetic implant tissue that has been treated with a capping agent, wherein, said tissue is dehydrated with a glycerol solution. - View Dependent Claims (26)
-
Specification